Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Nastya Kharlamova"'
Autor:
Francesca Faustini, Nicky Dunn, Nastya Kharlamova, Malin Ryner, Annette Bruchfeld, Vivianne Malmström, Anna Fogdell-Hahn, Iva Gunnarsson
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-13 (2021)
Abstract Background Anti-drug antibodies (ADAs) can impact on the efficacy and safety of biologicals, today used to treat several chronic inflammatory conditions. Specific patient groups may be more prone to develop ADAs. Rituximab is routinely used
Externí odkaz:
https://doaj.org/article/b7257dfa012e4aaa8b14f9ea4767b718
Autor:
Ildikó Tar, Éva Csősz, Edit Végh, Karin Lundberg, Nastya Kharlamova, Boglárka Soós, Zoltán Szekanecz, Ildikó Márton
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract Periodontal disease (PD) can be an important precipitating factor in the production of citrullinated proteins. Its importance is emphasized, but it is not the only way to produce citrullinated proteins. The aim of the current study was to de
Externí odkaz:
https://doaj.org/article/d0cb1d8048684778a84d973d065145b9
Autor:
Natalia Sherina, Charlotte de Vries, Nastya Kharlamova, Natalie Sippl, Xia Jiang, Boel Brynedal, Elin Kindstedt, Monika Hansson, Linda Mathsson-Alm, Lena Israelsson, Ragnhild Stålesen, Saedis Saevarsdottir, Rikard Holmdahl, Aase Hensvold, Gunnar Johannsen, Kaja Eriksson, Federica Sallusto, Anca I. Catrina, Johan Rönnelid, Caroline Grönwall, Tülay Yucel-Lindberg, Lars Alfredsson, Lars Klareskog, Luca Piccoli, Vivianne Malmström, Khaled Amara, Karin Lundberg
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Based on the epidemiological link between periodontitis and rheumatoid arthritis (RA), and the unique feature of the periodontal bacterium Porphyromonas gingivalis to citrullinate proteins, it has been suggested that production of anti-citrullinated
Externí odkaz:
https://doaj.org/article/526e09f1b5cb4ce898b6e91a70579ed3
Autor:
Nastya Kharlamova, Nicky Dunn, Sahl K. Bedri, Svante Jerling, Malin Almgren, Francesca Faustini, Iva Gunnarsson, Johan Rönnelid, Rille Pullerits, Inger Gjertsson, Karin Lundberg, Anna Månberg, Elisa Pin, Peter Nilsson, Sophia Hober, Katharina Fink, Anna Fogdell-Hahn
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Patients with chronic inflammatory diseases are often treated with immunosuppressants and therefore are of particular concern during the SARS-CoV-2 pandemic. Serological tests will improve our understanding of the infection and immunity in this popul
Externí odkaz:
https://doaj.org/article/b02ef409303541f9853101f9e88bd0ef
Autor:
Nastya Kharlamova, Christina Hermanrud, Nicky Dunn, Malin Ryner, Karen Hambardzumyan, Nancy Vivar Pomiano, Per Marits, Inger Gjertsson, Saedis Saevarsdottir, Rille Pullerits, Anna Fogdell-Hahn
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
A subgroup of patients treated with infliximab lose response to the treatment and one reason for this is the development of anti-drug antibodies (ADA). If used optimally, measuring drug and ADA level could lead to a more personalized and efficient tr
Externí odkaz:
https://doaj.org/article/79dbf46073304c1b828a8088bc48196f
Autor:
Kaja Eriksson, Erik Lönnblom, Gregory Tour, Anna Kats, Piotr Mydel, Pierre Georgsson, Catharina Hultgren, Nastya Kharlamova, Ulrika Norin, Jörgen Jönsson, Anna Lundmark, Annelie Hellvard, Karin Lundberg, Leif Jansson, Rikard Holmdahl, Tülay Yucel-Lindberg
Publikováno v:
Journal of Translational Medicine, Vol 14, Iss 1, Pp 1-14 (2016)
Abstract Background An infection-immune association of periodontal disease with rheumatoid arthritis has been suggested. This study aimed to investigate the effect of pre-existing periodontitis on the development and the immune/inflammatory response
Externí odkaz:
https://doaj.org/article/f38aba8225b94c35af4fdb8c86813b92
Autor:
Chris Wincup, Nicky Dunn, Caroline Ruetsch-Chelli, Ali Manouchehrinia, Nastya Kharlamova, Meena Naja, Barbara Seitz-Polski, David A Isenberg, Anna Fogdell-Hahn, Coziana Ciurtin, Elizabeth C Jury
Publikováno v:
Rheumatology (Oxford, England).
Objectives High rates of anti-drug antibodies (ADA) to rituximab have been demonstrated in patients undergoing treatment for SLE. However, little is known with regard to their long-term dynamics, impact on drug kinetics and subsequent implications fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af5503c0f4ba5c6a8f493efd822e13a9
https://pubmed.ncbi.nlm.nih.gov/36370065
https://pubmed.ncbi.nlm.nih.gov/36370065
Autor:
Chris Wincup, Nicky Dunn, Caroline Ruetsch-Chelli, Ali Manouchehrinia, Nastya Kharlamova, Meena Naja, Barbara Seitz-Polski, David Isenberg, Anna Fogdell-Hahn, Coziana Ciurtin, Elizabeth Jury
Publikováno v:
Rheumatology. 61
Background/Aims A major limitation of biologic therapy is formation of anti-drug antibodies (ADA). We previously demonstrated that ADA to rituximab are more prevalent in patients undergoing treatment for systemic lupus erythematosus (SLE) than rheuma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26dac2f786fff800b04570e02bb79ca9
https://doi.org/10.1093/rheumatology/keac133.242
https://doi.org/10.1093/rheumatology/keac133.242
Autor:
Natalia, Sherina, Charlotte, de Vries, Nastya, Kharlamova, Natalie, Sippl, Xia, Jiang, Boel, Brynedal, Elin, Kindstedt, Monika, Hansson, Linda, Mathsson-Alm, Lena, Israelsson, Ragnhild, Stålesen, Saedis, Saevarsdottir, Rikard, Holmdahl, Aase, Hensvold, Gunnar, Johannsen, Kaja, Eriksson, Federica, Sallusto, Anca I, Catrina, Johan, Rönnelid, Caroline, Grönwall, Tülay, Yucel-Lindberg, Lars, Alfredsson, Lars, Klareskog, Luca, Piccoli, Vivianne, Malmström, Khaled, Amara, Karin, Lundberg
Publikováno v:
Frontiers in immunology. 13
Based on the epidemiological link between periodontitis and rheumatoid arthritis (RA), and the unique feature of the periodontal bacterium
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d43722e78a2aca698f045957cfbae0c4
https://pubmed.ncbi.nlm.nih.gov/35514991
https://pubmed.ncbi.nlm.nih.gov/35514991
Autor:
Malin Ryner, Iva Gunnarsson, Anna Fogdell-Hahn, Nastya Kharlamova, F. Faustini, Vivianne Malmström, Annette Bruchfeld, Nicky Dunn
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-13 (2021)
Arthritis Research & Therapy
Arthritis Research & Therapy
Background Anti-drug antibodies (ADAs) can impact on the efficacy and safety of biologicals, today used to treat several chronic inflammatory conditions. Specific patient groups may be more prone to develop ADAs. Rituximab is routinely used for ANCA-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c542232bbb4aa683f8e68a56662231c
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-178466
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-178466
